公开(公告)号：US07892833B2

公开(公告)日：2011-02-22

申请号：US11275263

申请日：2005-12-21

申请人： Bernd Hentsch ,  Alexander B. Maurer ,  Sascha Hövelmann ,  Monika Raab ,  Elke Martin

发明人： Bernd Hentsch ,  Alexander B. Maurer ,  Sascha Hövelmann ,  Monika Raab ,  Elke Martin

IPC分类号： C12N15/01 ,  G01N33/53

CPC分类号： A61K31/20 ,  A61K31/19 ,  A61K31/4436 ,  A61K31/505 ,  A61K2300/00

摘要： Compounds can be used to act as inhibitors of enzymes having histone deacetylase activity for the medical therapy of conditions which predispose a person for the development of a disease, such as but not limited to cancer, inflammatory or metabolic diseases. Such conditions are linked to genetically inherited mutations of crucial genes which predispose a person with this condition to develop the disease phenotype. Thus, such compounds can be used for a suppressive therapeutic approach—the SUPPRESSION THERAPY—in order to inhibit or delay the onset or progression of the genetically predisposed disorder. Furthermore, a clinically used medicament can be manufactured for the SUPPRESSION THERAPY of such inherited predisposing conditions.

摘要翻译： 化合物可用作具有组蛋白脱乙酰酶活性的酶的抑制剂，用于药物治疗易于使人发展疾病（例如但不限于癌症，炎性或代谢性疾病）的病症。 这种情况与关键基因的遗传遗传突变有关，这种突变使患有这种病症的人发展为疾病表型。 因此，这些化合物可以用于抑制性治疗方法 - 抑制疗法 - 以抑制或延缓遗传易感疾病的发作或进展。 此外，可以制造临床使用的药物用于这种遗传易感条件的抑制治疗。